Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2019 7
2020 3
2021 3
2022 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
Pasello G, Lorenzi M, Scattolin D, Del Conte A, Cecere F, Pavan A, Macerelli M, Polo V, Pilotto S, Santarpia M, Cumerlato E, Da Ros V, Targato G, Bortolami A, Bonanno L, Ferro A, Dal Maso A, Frega S, Guarneri V. Pasello G, et al. Among authors: pavan a. Oncologist. 2024 Mar 23:oyae043. doi: 10.1093/oncolo/oyae043. Online ahead of print. Oncologist. 2024. PMID: 38520745 Free article.
Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer.
Wang Y, Peng L, Zhao M, Xiong Y, Xue J, Li B, Huang Z, Liu X, Yang X, Song Y, Bing Z, Guo C, Tian Z, Gao C, Cao L, Cao Z, Li J, Jiang X, Si X, Zhang L, Li X, Zheng Z, Song M, Chen R, Lim WT, Pavan A, Romero A, Liang N, Yang H, Li S. Wang Y, et al. Among authors: pavan a. Transl Lung Cancer Res. 2022 Sep;11(9):1936-1950. doi: 10.21037/tlcr-22-629. Transl Lung Cancer Res. 2022. PMID: 36248331 Free PMC article.
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Zulato E, Del Bianco P, Nardo G, Attili I, Pavan A, Boscolo Bragadin A, Marra L, Pasello G, Fassan M, Calabrese F, Guarneri V, Conte PF, Indraccolo S, Bonanno L. Zulato E, et al. Among authors: pavan a. Br J Cancer. 2022 Nov;127(11):2034-2042. doi: 10.1038/s41416-022-01978-1. Epub 2022 Sep 29. Br J Cancer. 2022. PMID: 36175621 Free PMC article.
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
Lorenzi M, Ferro A, Cecere F, Scattolin D, Del Conte A, Follador A, Pilotto S, Polo V, Santarpia M, Chiari R, Pavan A, Dal Maso A, Da Ros V, Targato G, Vari S, Indraccolo S, Calabrese F, Frega S, Bonanno L, Conte PF, Guarneri V, Pasello G. Lorenzi M, et al. Among authors: pavan a. Oncologist. 2022 Mar 4;27(2):87-e115. doi: 10.1002/onco.13951. Oncologist. 2022. PMID: 35641222 Free PMC article.
Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome.
Pavan A, Ferro A, Fortarezza F, Schiavon M, Evangelista L, Pezzuto F, Lunardi F, Frega S, Bonanno L, Rea F, Guarneri V, Conte P, Calabrese F, Pasello G. Pavan A, et al. Oncologist. 2022 Mar 4;27(2):e199-e202. doi: 10.1093/oncolo/oyab047. Oncologist. 2022. PMID: 35641202 Free PMC article.
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.
Pasello G, Lorenzi M, Calvetti L, Oliani C, Pavan A, Favaretto A, Palazzolo G, Giovanis P, Zustovich F, Bonetti A, Bernardi D, Mandarà M, Aprile G, Crivellaro G, Sinigaglia G, Tognazzo S, Morandi P, Bortolami A, Marino V, Bonanno L, Guarneri V, Conte P. Pasello G, et al. Among authors: pavan a. Oncologist. 2022 Jun 8;27(6):e484-e493. doi: 10.1093/oncolo/oyac051. Oncologist. 2022. PMID: 35429394 Free PMC article.
Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study.
Dieci MV, Azzarello G, Zagonel V, Bassan F, Gori S, Aprile G, Chiarion-Sileni V, Lonardi S, Oliani C, Zaninelli M, Chiari R, Favaretto A, Pavan A, Di Liso E, Mioranza E, Baldoni A, Bergamo F, Maruzzo M, Ziampiri S, Inno A, Graziani F, Sinigaglia G, Celestino M, Conte P, Guarneri V; Veneto Oncology Network. Dieci MV, et al. Among authors: pavan a. Eur J Cancer. 2022 May;167:81-91. doi: 10.1016/j.ejca.2022.03.005. Epub 2022 Mar 18. Eur J Cancer. 2022. PMID: 35398759 Free PMC article.
24 results